Document ID: chunk:federal_register_of_legislation:F2017L01288:front:0:p2
Version: federal_register_of_legislation:F2017L01288
Segment Type: other
Provision Reference: 
Character Range: 3157–4830

to therapeutic goods that are haematopoietic progenitor cells derived from:
              (a) bone marrow;
              (b) peripheral blood;
              (c) cord blood that is processed beyond minimal manipulation; and
              (d) any tissue other than cord blood.
     7 Standard
         (1) The matters specified in this order constitute a standard for the purposes of subsection 10(1) of the Act in relation to therapeutic goods that are haematopoietic progenitor cells derived from cord blood.
         (2) For the purposes of this order, the requirements provided in the NetCord-FACT International Standards are specified as minimum requirements for the manufacture of therapeutic goods that are haematopoietic progenitor cells derived from cord blood.

     8 Transitional arrangements
         (1)  In this section –
          former standard means the instrument specified in Schedule 1, as in force immediately before the commencement of this order.
          transition period means the period beginning on the commencement of this order and ending on 30 September 2018.
         (2) Despite the repeal of the former standard made by section 5 of this order, that standard continues to apply for the duration of the transition period in relation to the manufacture of therapeutic goods that are haematopoietic progenitor cells derived from cord blood, if the cells comprising those goods were collected before or during the transition period.

Schedule 1 Repeal
(section 5)

Repeal of instrument
Item                  Instrument name and date of making                                                                                     Register ID